Aromatherapy

Abstract

Aromatherapy, which MeSH classifies under psychotherapy, is the therapeutic use of volatile plant essential oils to influence mood, cognition, and physiological arousal. This article treats it as a testbed for how an odor acts on the mind, along two routes: a pharmacological one, in which absorbed molecules such as rosemary's 1,8-cineole reach the nervous system, and a psychological one, carried by olfaction's direct limbic wiring and learned expectancy. The established effects are modest: ambient lavender lowers state anxiety, odors cue old autobiographical memories, and lemon balm eased agitation in dementia. Systematic reviews nonetheless find the broader claims thin once expectancy is controlled, so a positive result is not itself evidence of an intrinsic drug-like action. Three demonstrations let the reader cue a memory by scent, dose cognition with plasma cineole, and split an anxiolytic effect into pharmacological and expectancy parts.

Keywords: aromatherapy, olfaction, odor-evoked memory, essential oils, expectancy

Aromatherapy is the practice of using the volatile aromatic compounds of plant essential oils, by inhalation or by application to the skin, with the aim of improving psychological or physical well-being. In the Medical Subject Headings vocabulary it is catalogued as descriptor D019341, defined as the use of fragrances and essences from plants to affect or alter a person's mood or behavior and to facilitate physical, mental, and emotional well-being, with the oils administered through inhalation, massage, or simple direct application. The word carries a great deal of commercial and folk baggage, and it is worth separating two questions that popular accounts run together: whether a fragrance produces any measurable effect on the mind, which is a legitimate topic in the psychology of olfaction, and whether the branded therapeutic system called aromatherapy delivers the specific health benefits it advertises, which is a clinical claim that must be tested against controls. This article keeps the two apart. It follows the odor into the brain by way of the olfactory system's direct route to emotion and memory (Herz, 2009), examines the fragrance effects on cognitive performance and on anxiety that survive controlled study, weighs the clinical evidence and its limits, and separates the pharmacological action of the molecules from the expectancy and learned-association effects that so often carry the result.

What Aromatherapy Is

Aromatherapy in its modern branded form is a twentieth-century invention, but the underlying claim it makes is old and testable: that a smell can change how a person feels and thinks. Stripping away the commerce, the scientific question is mechanistic, and Rachel Herz, reviewing the field, framed it as a fork (Herz, 2009). A fragrance might act pharmacologically, its volatile molecules absorbed through the nasal mucosa or the lungs into the bloodstream, crossing into the central nervous system and acting on it much as a drug would, independent of whether the person likes the smell or knows it is there. Or it might act psychologically, through the meaning the odor has acquired: a scent linked in the past to calm evokes calm, a scent a person is told is relaxing relaxes them, and the effect is carried by learned association and expectancy rather than by the chemistry reaching the brain. The two are not exclusive, and disentangling them is the central methodological problem of the field, because a study that shows a lavender scent reduced anxiety has shown nothing about mechanism unless it also controlled what the participant believed.

The distinction matters because it decides what a positive result means. If the action is pharmacological, the effect should appear even when the odor is delivered below the threshold of conscious detection or when the person is told nothing, and it should track the dose of active compound in the body. If the action is psychological, the effect should depend on the person's beliefs and prior associations and should vanish or reverse when those are manipulated, regardless of the molecule. Herz argued that for most claimed aromatherapy effects the psychological route dominates, and that the burden of proof for an intrinsic pharmacological action is a demonstration that survives the removal of expectancy (Herz, 2009). The sections that follow take the two routes in turn, beginning with the one that gives olfaction its special psychological force.

The Olfactory Route to Emotion and Memory

Olfaction is wired to emotion and memory more directly than any other sense, and this anatomy is what makes a scent psychologically potent. The other senses relay through the thalamus before reaching the cortex; olfactory signals reach the amygdala and the hippocampal formation with far fewer synapses intervening, so an odor has quick, privileged access to the structures that assign emotional value and lay down episodic memory. The behavioural signature of this wiring is the finding, popularly the Proust phenomenon, that odors are unusually effective cues to autobiographical memory. Simon Chu and John Downes showed that when older adults retrieved memories cued by odors, the recollections were older, more vivid, and more emotionally charged than memories cued by the odor's name or by a picture, and that the odor cue in particular pulled memories from the first decade of life, before the reminiscence bump where verbally cued memories cluster (Chu & Downes, 2002). The demonstration below lets the reader switch a retrieval cue between an odor, a word, and a picture and watch the distribution of memory ages shift.

The emotional charge of these memories has a neural correlate. Rachel Herz and colleagues scanned participants while they smelled a perfume that was personally associated with an emotional memory and, separately, while they viewed its visual counterpart, and found that the odor condition produced greater activation in the amygdala and the hippocampal region than the visual condition, evidence that the odor route to an emotional memory is not merely reported as more vivid but engages the emotion and memory systems more strongly (Herz et al., 2004). This is the psychological route in its purest form: the effect of the scent is entirely a matter of what it has been associated with. The associations themselves are learned rather than given. The foundational work of Trygg Engen established that odor–emotion pairings are acquired through experience, not innate, so that the same molecule is pleasant to one person and repellent to another depending on the history each brings to it, a conclusion that undercuts any claim that a fragrance carries an intrinsic, universal mood effect. Odor associations are, in effect, a form of classical conditioning, with the neutral scent coming to evoke the response of whatever it accompanied.

Fragrance and Cognitive Performance

The pharmacological route is best demonstrated where a fragrance changes performance on an objective cognitive task rather than a mood rating, and the clearest case is rosemary. Mark Moss and colleagues seated volunteers in a cubicle scented with rosemary or lavender essential oil, or with no odor, and tested them on speed and accuracy of attention and memory. Rosemary aroma enhanced performance on measures of secondary memory and alertness relative to no odor, while lavender impaired working-memory performance and slowed reaction time, a double dissociation that argues against a single generic effect of pleasant smells and for something more specific to the chemistry of each oil (Moss et al., 2003). That the two oils moved cognition in opposite directions is itself an argument for a pharmacological component, since a pure expectancy account would predict that any oil believed to be beneficial should help.

The mechanistic follow-up made the pharmacological case concrete. Moss and Oliver reasoned that if rosemary acts as a drug, its cognitive effect should track the concentration of an absorbed active compound in the body, not merely the presence of a smell. They exposed participants to rosemary aroma, measured the blood plasma level of 1,8-cineole, a principal volatile terpene of rosemary, and found that the plasma concentration correlated with speed and accuracy of performance on serial-subtraction and other tasks, with the relationship holding after mood was accounted for (Moss & Oliver, 2012). A dose of an inhaled compound measured in the blood, predicting a change in cognition, is the signature of a genuine pharmacological action, and it is the strongest single piece of evidence that at least some fragrance effects are not merely expectancy. The demonstration below models that chain, letting the reader set an exposure time, watch plasma cineole rise toward saturation, and read off the predicted performance gain.

Anxiety, Mood, and the Ambient Scent

The most reliably replicated aromatherapy effect is a modest reduction in state anxiety from ambient lavender, and the anxiety-provoking waiting room has been its natural laboratory. Johann Lehrner and colleagues piped orange or lavender odor into a dental clinic waiting area and found that patients exposed to either scent reported lower state anxiety and a more positive mood than patients who waited in an unscented room, a clean demonstration of an anxiolytic ambient-scent effect under naturalistic conditions (Lehrner et al., 2005). The dental setting was used again by Maria Kritsidima and colleagues, whose cluster-randomised trial found that the smell of lavender lowered patients' state anxiety on arrival, though it did not change their anticipatory anxiety about future dental visits, a distinction that suggests the scent acts on present feeling rather than on cognitively elaborated worry (Kritsidima et al., 2010).

Pooled across studies, the anxiolytic signal survives. A systematic review and meta-analysis by Davide Donelli and colleagues gathered controlled trials of lavender for anxiety and concluded that lavender, and in particular a standardised oral preparation but also inhaled forms, produced a measurable reduction in anxiety symptoms relative to controls, while the authors were careful to flag the heterogeneity of the trials and the risk of bias in many of them (Donelli et al., 2019). The honest reading is that the effect is real and small, better established for anxiety than for any other outcome, and that its size in any given study depends heavily on what the participants expected. The demonstration below makes that dependence explicit, splitting a scent's total anxiolytic effect into a fixed pharmacological part and an expectancy part that swings with what the person is told.

Clinical Evidence and Its Limits

Beyond the anxiety of a waiting room, aromatherapy has been tested as a clinical intervention, most seriously in dementia care, where an agent that could calm agitation without the sedation and mortality risk of antipsychotics would be genuinely valuable. Clive Ballard and colleagues ran a double-blind, placebo-controlled trial of Melissa officinalis, lemon balm, essential oil applied in a lotion to patients with severe dementia and clinically significant agitation, and found that the aromatherapy group showed a substantial reduction in agitation relative to a placebo lotion, with improvements also in quality-of-life indices and without the adverse effects of pharmacological sedation (Ballard et al., 2002). It remains one of the better-designed positive trials in the field, precisely because the double-blind, placebo-controlled structure addresses the expectancy problem that undermines weaker studies.

The wider evidence base is less encouraging. An early systematic review by Brian Cooke and Edzard Ernst gathered the controlled trials then available and concluded that aromatherapy produced a mild, transient reduction in anxiety but that the evidence did not support its use for any other therapeutic claim, and that the effects on anxiety were of a magnitude and duration consistent with relaxation rather than with a specific medical action (Cooke & Ernst, 2000). More than a decade later the picture for dementia specifically had, if anything, weakened: a Cochrane systematic review led by Lene Forrester examined randomised trials of aromatherapy for dementia and found the evidence inconsistent and of low quality, with the better-controlled trials failing to replicate the early benefits and no firm conclusion possible about efficacy (Forrester et al., 2014). The trajectory, from a promising single trial to an equivocal review as methodology tightens, is the familiar shape of a small effect entangled with expectancy, and it is the reason the field's most careful voices treat aromatherapy as a relaxant with real but limited value rather than as a treatment.

Mechanisms: Pharmacology versus Expectancy

The two routes introduced at the outset can now be given their mechanistic detail. On the pharmacological side, inhaled volatile compounds are absorbed across the respiratory and nasal epithelia into the systemic circulation and can cross the blood–brain barrier, and Tsz Kin Fung and colleagues reviewed the physiological pathways by which essential-oil constituents act on mood, emphasising an interaction between the olfactory and respiratory systems and the nervous system and cataloguing the receptor and neurotransmitter targets, including modulation of the GABA system, through which compounds such as linalool, the principal terpene alcohol of lavender, could exert a genuine anxiolytic action (Fung et al., 2021). This is the biochemical substrate that a plasma-cineole correlation (Moss & Oliver, 2012) implies must exist. Psychophysiological recording offers a complementary window: Kandhasamy Sowndhararajan and Songmun Kim reviewed studies using the electroencephalogram to index the brain's response to fragrances and found that different odors produce distinguishable changes in cortical electrical activity and in self-reported and autonomic arousal, showing that fragrances do register measurably in the nervous system even where a specific clinical benefit is unproven (Sowndhararajan & Kim, 2016).

On the psychological side, the effect is carried by expectancy and by the learned associations whose acquisition Engen documented, and Herz's central methodological point is that these are not nuisance variables to be minimised but often the main effect itself (Herz, 2009). A person told that a scent is invigorating performs as if invigorated; the same scent labelled as relaxing relaxes. This is why the plasma-cineole result matters so much: by tying the outcome to a measured internal dose rather than to the mere presence of a smell, it isolates a component of the effect that expectancy cannot easily explain. Table 1 sets the two routes side by side with their signatures, their evidence, and the control that separates them.

Table 1

Two Routes by Which a Fragrance Acts on the Mind

Note. The two routes usually operate together; the columns describe the pure cases and the experimental manipulation that would separate them. A positive aromatherapy result implicates the pharmacological route only if it survives the control in the last row.

Worked Examples

The cineole demonstration is worth computing by hand, because it shows how a pharmacological dose–response turns exposure time into a predicted cognitive gain and reproduces exactly what the demonstration draws. Model the plasma concentration of 1,8-cineole after t minutes in a rosemary-scented room as a first-order approach to a saturation ceiling, the standard shape for an inhaled compound equilibrating between air and blood:

C(t) = C_max × (1 − e^−t/τ)

with a ceiling C_max = 30 (in illustrative ng/mL) and a time constant τ = 10 minutes. Take the cognitive gain, expressed as a percentage improvement in serial-subtraction speed, to be proportional to the plasma concentration, ΔP = k × C, with k = 0.30 percentage points per unit. At one time constant, t = 10 minutes, the exponent is −1, so C = 30 × (1 − e⁻¹) = 30 × (1 − 0.368) = 30 × 0.632 = 18.96, and the predicted gain is ΔP = 0.30 × 18.96 = 5.69 percent. Double the exposure to t = 20 minutes, two time constants, and C = 30 × (1 − e⁻²) = 30 × (1 − 0.135) = 30 × 0.865 = 25.94, so ΔP = 0.30 × 25.94 = 7.78 percent.

The diminishing return is the point. Doubling the exposure from 10 to 20 minutes did not double the gain; it moved it from 5.69 to 7.78 percent, because the concentration is climbing a saturating curve and each additional minute adds less. At full saturation, t large, C approaches C_max = 30 and the gain approaches its ceiling of 0.30 × 30 = 9.0 percent, which no finite exposure quite reaches. This saturating dose–response is exactly what a pharmacological account predicts and an expectancy account does not, since belief has no reason to follow an exponential approach to a plasma ceiling; setting the demonstration's exposure slider to 10 and 20 minutes reproduces the 5.69 and 7.78 percent readouts point for point.

The expectancy demonstration rewards the same treatment, because it shows how a single positive anxiety result can be built almost entirely from belief. Model the total reduction in state anxiety, in points on a standard scale, as the sum of a fixed pharmacological part and a belief-scaled expectancy part:

ΔA = P + B × E

with an intrinsic pharmacological reduction P = 3 points, an expectancy amplitude E = 6 points, and a belief coefficient B set by what the participant is told: B = +1.0 when the scent is described as relaxing, B = +0.25 when nothing is said, and B = −0.5 when it is described as stimulating. Told the scent is relaxing, the participant's anxiety falls by ΔA = 3 + 6 × 1.0 = 9 points. Told nothing, it falls by ΔA = 3 + 6 × 0.25 = 4.5 points. Told the scent is stimulating, it falls by ΔA = 3 + 6 × (−0.5) = 3 − 3 = 0 points: the expectancy exactly cancels the pharmacology and the scent appears inert.

The lesson is that the same oil, with the same intrinsic action of 3 points, can be made to look like a strong anxiolytic or like nothing at all purely by changing the instruction, and that the reported effect size in an uncontrolled study is therefore mostly a measurement of expectancy (Herz, 2009). It also shows why the pharmacological floor matters: even under the discouraging instruction the true drug-like action does not go negative, it is merely masked. The demonstration's belief control steps its readout through 9, 4.5, and 0 points as the instruction changes, reproducing these figures point for point, and its pharmacology slider raises or lowers the floor beneath all three.

Discussion

Aromatherapy is a useful case for cognitive psychology precisely because its popular reputation so far outruns its evidence, which forces the discipline to do what it does well: separate a real effect from the belief that surrounds it. The genuine findings are worth keeping. Olfaction's direct wiring to the limbic system makes odors exceptional cues to emotional autobiographical memory, a robust laboratory phenomenon with a clean neural signature (Chu & Downes, 2002; Herz et al., 2004). Some fragrance effects on cognition are pharmacological in the strict sense, tied to a measured concentration of an absorbed compound rather than to the mere presence of a smell (Moss & Oliver, 2012). And ambient lavender produces a small, replicable reduction in state anxiety (Lehrner et al., 2005; Donelli et al., 2019).

What the field does not support is the inference from any of these to the broad therapeutic claims made under the aromatherapy label, because the dominant mechanism for most claimed effects is psychological, and a psychological effect does not transfer across the situations, doses, and outcomes that a pharmacological one would (Herz, 2009; Cooke & Ernst, 2000). The methodological moral generalises well beyond fragrance. Whenever a manipulation carries a strong expectation, its measured effect is a sum of what it does and what the person believes it does, and only a design that varies the belief while holding the manipulation fixed can tell the two apart. The best aromatherapy studies, the double-blind dementia trial and the plasma-cineole correlation, are exactly the ones that build in that separation, and they are why the honest verdict is neither dismissal nor endorsement but a narrow, mechanism-specific account of when a smell moves the mind and why. The three demonstrations above are illustrative models of that account, not fits to a particular data set.

Current Directions

The live research questions are about mechanism and rigour rather than about whether fragrances do anything at all. On the pharmacological side, the effort is to move from correlation to identified targets: Fung and colleagues' synthesis of the receptor and neurotransmitter pathways, including the GABAergic action attributed to lavender's linalool, sets an agenda of specifying which constituent acts on which system, so that an essential oil can be treated as a mixture of candidate compounds with definable pharmacology rather than as an undifferentiated scent (Fung et al., 2021). Psychophysiological methods are being used to give that programme objective endpoints; the electroencephalographic literature reviewed by Sowndhararajan and Kim aims to replace self-report with measurable cortical and autonomic signatures of a fragrance's effect, which is one way to sidestep the expectancy confound that self-report cannot escape (Sowndhararajan & Kim, 2016). On the clinical side, the meta-analytic turn exemplified by Donelli and colleagues reflects a field trying to extract a stable effect size for the one outcome, anxiety, where the signal is strongest, while being explicit about the heterogeneity and risk of bias that still limit confidence (Donelli et al., 2019). The unifying direction is the demand that any positive result be shown to survive the removal of expectancy before it is credited to the chemistry.

Common Misconceptions

Aromatherapy oils have intrinsic, universal mood effects.

Odor–emotion associations are learned through experience rather than innate, so the same molecule can be pleasant to one person and aversive to another depending on individual history; much of a fragrance's mood effect is carried by expectancy and prior association rather than by a fixed property of the oil (Herz, 2009).

A study showing lavender reduced anxiety proves the oil acts pharmacologically.

Not unless it controlled what participants believed. An anxiolytic result implicates the chemistry only if it survives manipulation of expectancy or below-awareness delivery; otherwise the measured effect is a sum of pharmacology and belief that the design cannot separate (Herz, 2009; Cooke & Ernst, 2000).

Aromatherapy is an established treatment for dementia.

A well-designed early trial of lemon balm was encouraging (Ballard et al., 2002), but a Cochrane review found the randomised evidence overall inconsistent and of low quality, with better-controlled trials failing to replicate the benefit (Forrester et al., 2014). It is a candidate relaxant, not a proven therapy.

All pleasant fragrances help thinking.

Different oils move cognition in different directions: rosemary aroma enhanced memory and alertness while lavender impaired working memory and slowed responses in the same paradigm, a dissociation incompatible with a generic effect of pleasant smell and evidence of oil-specific chemistry (Moss et al., 2003).

Glossary

1,8-Cineole.

A principal volatile terpene of rosemary, also called eucalyptol; its concentration in blood plasma after aroma exposure correlates with cognitive performance, evidence of a pharmacological route of action.

Amygdala.

An almond-shaped structure of the limbic system that assigns emotional significance to stimuli; olfactory input reaches it unusually directly, which is part of why odors carry strong emotional weight.

Aromatherapy.

The therapeutic use of the volatile aromatic compounds of plant essential oils, by inhalation or topical application, to influence mood, cognition, or physiological state; MeSH descriptor D019341.

Classical conditioning.

Learning in which a neutral stimulus, through repeated pairing, comes to evoke a response originally produced by another stimulus; the mechanism by which a scent acquires its learned emotional associations.

Episodic memory.

Memory for specific personally experienced events set in a time and place; odors are unusually effective cues to it, especially for events from early life.

Essential oil.

A concentrated liquid of volatile aromatic compounds extracted from a plant, the working material of aromatherapy; each oil is a mixture of many constituents with distinct chemistry.

Expectancy effect.

A change in outcome produced by a person's belief about what an intervention will do, independent of any intrinsic action; in aromatherapy it can equal or exceed the pharmacological effect and must be controlled to interpret a result.

Linalool.

A terpene alcohol that is a principal constituent of lavender oil; a candidate pharmacological agent for lavender's anxiolytic effect, proposed to act on the GABA system.

Olfaction.

The sense of smell; distinctive among the senses for reaching emotion and memory structures with fewer intervening relays, which underlies the psychological potency of odors.

Pharmacological route.

The pathway by which absorbed volatile molecules act directly on the nervous system, as a drug would; its signature is an effect that tracks the internal dose and does not require the person's awareness or belief.

Proust phenomenon.

The observation that odors evoke autobiographical memories that are older, more vivid, and more emotionally charged than memories cued by words or images, named for Proust's madeleine.

Psychological route.

The pathway by which an odor acts through its acquired meaning, via learned association and expectancy, rather than through chemistry reaching the brain; its signature is dependence on belief and prior experience.

Reminiscence bump.

The tendency for autobiographical memories to cluster in adolescence and early adulthood; odor-cued memories are notable for falling earlier, in the first decade of life, than this typical peak.

State anxiety.

A transient level of anxiety felt in a particular situation, as distinct from a stable trait; the outcome on which aromatherapy's evidence is strongest, reduced modestly by ambient lavender.

Key Researchers

Clive G. Ballard. Professor of Age-Related Diseases and Pro-Vice-Chancellor at the University of Exeter; he ran the double-blind, placebo-controlled trial showing that lemon balm aromatherapy reduced agitation in severe dementia without the sedation of antipsychotics, one of the field's better-designed positive trials. Faculty Page - ORCID - Google Scholar - Wikipedia

Simon Chu. Psychologist at the University of Central Lancashire; his work on odor-cued autobiographical memory demonstrated that smells evoke older, more emotional, and more vivid recollections than other cues, supplying the empirical core of the Proust phenomenon. ORCID - Google Scholar

Trygg Engen. Norwegian-American experimental psychologist (1926–2009) at Brown University; he founded the modern psychophysics of smell, showing that odor recognition memory resists forgetting and that odor–emotion associations are learned rather than innate, a foundational challenge to the premise of intrinsic fragrance effects. Obituary

Edzard Ernst. Emeritus Professor of Complementary Medicine at the University of Exeter and the field's leading evidence-based critic; his systematic review with Cooke concluded that aromatherapy's anxiety-reducing effects are mild and transient and that the evidence does not support therapeutic claims beyond relaxation. Personal Site - Google Scholar - Wikipedia

Rachel S. Herz. Cognitive neuroscientist at Brown University and a leading authority on the psychology of smell; she distinguished the pharmacological from the psychological routes to fragrance effects on mood and physiology, and her neuroimaging work localised the emotional potency of odor-evoked memory to the amygdala and hippocampus. Faculty Page - Wikipedia

Johann Lehrner. Neuropsychologist at the Medical University of Vienna; his controlled dental-office study showed that ambient orange and lavender odors lowered state anxiety and improved mood in waiting patients, one of the cleaner demonstrations of an anxiolytic ambient-scent effect. ORCID - Google Scholar

Mark Moss. Professor of Psychology and Head of Department at Northumbria University; he showed that rosemary aroma enhances aspects of cognitive performance while lavender impairs them, and later tied the effect to blood plasma levels of the rosemary terpene 1,8-cineole, giving the phenomenon a candidate pharmacological mechanism. ORCID - Google Scholar

Frequently Asked Questions

What is aromatherapy? Aromatherapy is the therapeutic use of the volatile aromatic compounds of plant essential oils, delivered by inhalation or applied to the skin, to influence mood, cognition, or physiological arousal (Herz, 2009). MeSH catalogues it as descriptor D019341 and files it under psychotherapy as an indexing convenience, not because it is a talking treatment.

Do essential oils actually affect the mind, or is it all placebo? Both routes are real. Some effects are pharmacological, tracking a measured internal dose of an absorbed compound, as when plasma 1,8-cineole from rosemary predicts cognitive performance (Moss & Oliver, 2012); others are psychological, carried by expectancy and learned association (Herz, 2009). A given result is not placebo, but it is only evidence of chemistry if it survives control of belief.

Why do smells trigger such vivid memories? Olfaction reaches the amygdala and hippocampal region more directly than the other senses, giving odors privileged access to emotion and episodic memory. Odor-cued recollections are older, more vivid, and more emotional than memories cued by words or pictures, the Proust phenomenon (Chu & Downes, 2002), with a neuroimaging correlate of stronger amygdala and hippocampal activation (Herz et al., 2004).

Does rosemary really improve memory? In controlled testing, rosemary aroma enhanced measures of memory and alertness while lavender impaired working memory in the same paradigm (Moss et al., 2003), and the cognitive benefit correlated with blood plasma levels of the rosemary terpene 1,8-cineole (Moss & Oliver, 2012). The effect is modest and specific, not a general boost.

Does lavender reduce anxiety? It produces a small, replicable reduction in state anxiety. Ambient lavender lowered anxiety in dental waiting rooms (Lehrner et al., 2005; Kritsidima et al., 2010), and a meta-analysis found a measurable anti-anxiety effect across trials while cautioning about their heterogeneity and risk of bias (Donelli et al., 2019).

Is aromatherapy an effective treatment for dementia? The evidence is mixed. An early double-blind trial of lemon balm reduced agitation in severe dementia (Ballard et al., 2002), but a Cochrane review judged the overall randomised evidence inconsistent and of low quality, with better-controlled trials not replicating the benefit (Forrester et al., 2014). It is a promising relaxant rather than a proven therapy.

Why does MeSH classify aromatherapy under psychotherapy? The Medical Subject Headings tree places aromatherapy beneath psychotherapy as an indexing location within its hierarchy of mind-body and complementary therapies, not as an assertion that it works by the same verbal mechanism. It also sits under phytotherapy and sensory art therapies, reflecting an indexing convenience rather than a single true kind.

How can I tell a genuine drug-like effect of an oil from expectancy? Vary the belief while holding the odor fixed, or deliver the odor below the threshold of awareness. A pharmacological effect should appear without the person's knowledge and should track the internal dose; a psychological effect should swing with what the person is told and disappear when the belief is removed (Herz, 2009). The strongest evidence, a plasma-concentration correlation, builds that separation in.

References